ENTRY       D11967            Mixture   Drug
NAME        Daratumumab and hyaluronidase;
            Daratumumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination);
            Daratumumab and hyaluronidase-fihj;
            Darzalex faspro (TN);
            Darzquro (TN)
PRODUCT     DARZALEX FASPRO (Janssen Biotech)
COMPONENT   Daratumumab [DR:D10777], (Hyaluronidase [DR:D04456] | Hyaluronidase (human recombinant) [DR:D06604])
REMARK      Therapeutic category: 4291
            ATC code: L01FC01
            Product: D11967<JP/US>
EFFICACY    Antineoplastic
  DISEASE   Multiple myeloma [DS:H00010]
            Light chain amyloidosis [DS:H02499]
  TYPE      Monoclonal antibody, combination
COMMENT     Treatment of light chain (AL) amyloidosis
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FC CD38 (Clusters of Differentiation 38) inhibitors
                 L01FC01 Daratumumab
                  D11967  Daratumumab and hyaluronidase &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Daratumumab/ Hyaluronidase
                D11967  Daratumumab and hyaluronidase
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D11967  Daratumumab and hyaluronidase
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11967
///
